TP53 and breast carcinoma: The EMBER platform [23] and other post-2020 studies [24,25,26] highlight heterogeneity in breast cancer subtypes and transcriptomic signatures, reinforcing the relevance of TP73 isoform analysis and its interplay with TP53 status.